secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001558370-23-016149
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor announces positive FDA Type-B meeting confirming Phase 3 path to BLA for CAP-1002 in DMD
--------------------------------------------------------------------------------

- FDA aligned on HOPE-3 trial design; key endpoints unchanged; BLA submission targeted for 2025.
- HOPE-3 enrollment ~90% complete (52 of ~58 patients dosed); interim analysis expected Q4 2023.
- Topline data for HOPE-3 expected Q4 2024; BLA supported by product from Los Angeles site.
- San Diego site work continues for potential commercial demand; CAP-1002 holds Orphan Drug and RMAT designations.
- Company eligible for Priority Review Voucher if CAP-1002 receives FDA approval for DMD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023016149/0001558370-23-016149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023016149/capr-20230929x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-016149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer